Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Blueprint Medicines Q4 EPS $(1.82) Beats $(2.04) Estimate, Sales $71.96M Beat $66.64M Estimate

Author: Benzinga Newsdesk | February 15, 2024 08:04am
Blueprint Medicines (NASDAQ:BPMC) reported quarterly losses of $(1.82) per share which beat the analyst consensus estimate of $(2.04) by 10.78 percent. This is a 31.32 percent increase over losses of $(2.65) per share from the same period last year. The company reported quarterly sales of $71.96 million which beat the analyst consensus estimate of $66.64 million by 7.98 percent. This is a 85.55 percent increase over sales of $38.78 million the same period last year.

Posted In: BPMC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist